Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Strikingly Reduced Toxicities of Fotemustine-Based Chemotherapeutics Than High-Dose Methotrexate-Containing Regimens with Comparable Efficacy

Blood (2024) 144 (Supplement 1): 6458.

https://doi.org/10.1182/blood-2024-202107

Published: 2024

Journal Articles

A Phase I/II Study of Orelabrutinib Combined with Anti-Programmed Cell Death Protein-1 Antibody and Fotemustine for Patients with Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL)

Xudong Zhang, Wenhua Wang, Shanshan Ma, Mengke Fan, Linan Zhu, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Zhaoming Li, Jiaqin Yan, Mingzhi Zhang

Blood (2022) 140 (Supplement 1): 12075–12076.

https://doi.org/10.1182/blood-2022-159383

Published: 2022

Journal Articles

Anti-PD-1-Antibody (Tislelizumab) Combined with Deacetylase Inhibitor (Chidamide), Lenalidomide and Etoposide for the Treatment of Refractory/Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single -Arm, Phase II Trial

Lei Zhang, Xiyang Liu, Xinhua Wang, Yu Chang, Xiaorui Fu, Xin Li, Ling Li, Jiaqin Yan, Feifei Nan, Xiaolong Wu, Linan Zhu, Zhenchang Sun, Hui Yu, Mingzhi Zhang

Blood (2021) 138 (Supplement 1): 1368.

https://doi.org/10.1182/blood-2021-152020

Published: 2021

Journal Articles

Fotemustine-Based in Combination with Rituximab As First-Line Induction Chemotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma:a Prospective Phaseii Trial

Blood (2020) 136 (Supplement 1): 5.

https://doi.org/10.1182/blood-2020-137449

Published: 2020